{"id":583659,"date":"2026-02-12T02:49:25","date_gmt":"2026-02-12T02:49:25","guid":{"rendered":"https:\/\/www.europesays.com\/us\/583659\/"},"modified":"2026-02-12T02:49:25","modified_gmt":"2026-02-12T02:49:25","slug":"roche-details-non-inferiority-of-btk-inhibitor-in-multiple-sclerosis-trial-endpoints-news","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/583659\/","title":{"rendered":"Roche details non-inferiority of BTK inhibitor in multiple sclerosis trial – Endpoints News"},"content":{"rendered":"
    \n
  1. Roche details non-inferiority of BTK inhibitor in multiple sclerosis trial<\/a>  Endpoints News<\/li>\n
  2. Roche unveils data behind BTK inhibitor’s phase 3 multiple sclerosis win in Ocrevus trial<\/a>  Fierce Biotech<\/li>\n
  3. ACTRIMS 2026: Fenebrutinib matches Ocrevus in PPMS trial<\/a>  Multiple Sclerosis News Today<\/li>\n
  4. Genentech plans NDA for multiple sclerosis pill with study win<\/a>  BioWorld MedTech<\/li>\n
  5. RO: Fenebrutinib matched ocrelizumab in PPMS efficacy and offers a promising oral high-efficacy MS option<\/a>  TradingView<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"Roche details non-inferiority of BTK inhibitor in multiple sclerosis trial  Endpoints News Roche unveils data behind BTK inhibitor’s phase…\n","protected":false},"author":3,"featured_media":583660,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[34],"tags":[252947,252948,252950,210,1060,43462,252946,44350,252945,60244,252944,178212,252949,67,132,68],"class_list":["post-583659","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-btk-inhibitor","tag-fenebrutinib","tag-fentrepid","tag-health","tag-medication","tag-multiple-sclerosis","tag-ocrevus","tag-pharma","tag-ppms","tag-rd","tag-roche","tag-sanofi","tag-tolebrutinib","tag-united-states","tag-unitedstates","tag-us"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/116055386662081754","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/583659","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=583659"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/583659\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/583660"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=583659"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=583659"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=583659"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}